Literature DB >> 11720482

Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

X M Liu1, L G Wang, W Kreis, D R Budman, L M Adams.   

Abstract

The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells. We demonstrated that ERK2 was activated rapidly by vinorelbine, and was inhibited by either paclitaxel or estramustine. A 3-fold increase of ERK2 kinase activity was observed within 30 min when MCF-7 cells were treated with 0.1 microM vinorelbine. In contrast, the same treatment with paclitaxel resulted in a significant decrease of ERK2 kinase activity. We also demonstrated that elevated bcl-2 phosphorylation induced by vinorelbine is paralleled by decrease of a complex formation between bcl-2 and bax, cleavage of poly (ADP) ribose polymerase (PARP) protein, activation of caspase-7, and apoptosis. The levels of bcl-2 phosphorylation, bax, and PARP were not significantly affected by 2'-amino-3'-methoxyflavone (PD 98059), an ERK kinase specific inhibitor. Thus, our data suggest that the apoptosis induced by vinorelbine in MCF-7 cells is mediated through the bcl-2 phosphorylation/bax/caspases pathways, and that activation of ERK2 by vinorelbine does not directly lead to the drug-mediated apoptosis. Since decrease of PARP occurred quickly following the treatment of MCF-7 cells with either 0.1 microM of vinorelbine or paclitaxel, this protein may serve as an early indicator of apoptosis induced not only by DNA damaging agents, but also by antimicrotubule drugs. Copyright 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720482      PMCID: PMC2375254          DOI: 10.1054/bjoc.2001.2107

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  44 in total

1.  Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.

Authors:  D R Budman; A Calabro; L G Wang; X M Liu; L Stiel; L M Adams; W Kreis
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

Review 2.  The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.

Authors:  L G Wang; X M Liu; W Kreis; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

3.  Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7.

Authors:  M Germain; E B Affar; D D'Amours; V M Dixit; G S Salvesen; G G Poirier
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

4.  BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.

Authors:  K Yamamoto; H Ichijo; S J Korsmeyer
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

5.  Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells.

Authors:  M V Blagosklonny; P C Bishop; R Robey; T Fojo; S E Bates
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.

Authors:  L G Wang; X M Liu; D R Budman; W Kreis
Journal:  Biochem Pharmacol       Date:  1999-10-01       Impact factor: 5.858

7.  Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line.

Authors:  R Panvichian; K Orth; M J Pilat; M L Day; K C Day; C Yee; J M Kamradt; K J Pienta
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

8.  The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival.

Authors:  X Wang; J L Martindale; Y Liu; N J Holbrook
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

9.  2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation.

Authors:  H Attalla; J A Westberg; L C Andersson; H Adlercreutz; T P Mäkelä
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

10.  Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells.

Authors:  C H Lieu; C C Liu; T H Yu; K D Chen; Y N Chang; Y K Lai
Journal:  Cell Growth Differ       Date:  1998-09
View more
  6 in total

1.  Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells.

Authors:  Masaharu Hazawa; Kenji Takahashi; Koji Wada; Takao Mori; Norio Kawahara; Ikuo Kashiwakura
Journal:  Invest New Drugs       Date:  2009-09-26       Impact factor: 3.850

2.  A new lipid-based nano formulation of vinorelbine.

Authors:  Fatemeh Bahadori; Gülaçtı Topçu; Mehmet S Eroğlu; Hayat Onyüksel
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

3.  Evaluation of Therapeutic Potential of Eugenol-A Natural Derivative of Syzygium aromaticum on Cervical Cancer

Authors:  Arunava Das; Harshadha K; Dhinesh Kannan S K; Hari Raj K; Bindhu Jayaprakash
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27

4.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

5.  Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.

Authors:  X M Liu; J D Jiang; A C Ferrari; D R Budman; L G Wang
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

Review 6.  Microtubules and their role in cellular stress in cancer.

Authors:  Amelia L Parker; Maria Kavallaris; Joshua A McCarroll
Journal:  Front Oncol       Date:  2014-06-18       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.